ReviewCancers2024
Cutaneous Squamous Cell Carcinoma: An Updated Review.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natural Compounds for the Treatment of Cutaneous Squamous Cell Carcinoma: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Rapidly growing well-differentiated cutaneous squamous cell carcinoma of the scalp in a patient who was immunosuppressed.Skin health and disease · 2026Article
- Review
- Economic evaluation of added neoadjuvant cemiplimab to upfront wide local excision for advanced cutaneous squamous cell carcinoma of the head and neck.JID innovations : skin science from molecules to population health · 2026Article
- Cutaneous Squamous Cell Carcinoma Across the Pre-COVID-19, COVID-19 and Post-COVID-19 Eras: Epidemiology, Risk Stratification, Tumour Aggressiveness, and Clinical Outcomes.Dermatopathology (Basel, Switzerland) · 2026Article
- Lower Eyelid Cutaneous Squamous Cell Carcinoma: Oncologic Resection and Reconstruction With a Mustardé Rotation Flap.Cureus · 2026Article
- Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma.Nature communications · 2026Article
- Potential Efficacy of Luteolin in Cutaneous Squamous Cell Carcinoma: A Combined In Vitro and In Vivo Study.Biomolecules · 2026Article
- Beyond Binary Positivity: Spectrum of Nodal Tumor Burden in Sentinel Lymph Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma.Dermatopathology (Basel, Switzerland) · 2026Article
- Tumor Thickness and Histological Grade as Determinants of Sentinel Lymph Node Metastasis in Cutaneous Squamous Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- The Role of the TG2-GPR56 Complex in Cutaneous Squamous Cell Carcinoma (CSCC) Aggression and Therapeutic Resistance.International journal of molecular sciences · 2026Review
- Primary cutaneous squamous cell carcinoma of the neck mimicking tuberculous lymphadenitis.Discover oncology · 2026Article
- RB1 inactivation in cutaneous carcinomas.Histopathology · 2026Review
- Successful Treatment of Cutaneous Squamous Cell Carcinoma Complicated by Myelodysplastic Syndrome Using Combined ALA-PDT and Narrow-Margin Excision: A Case Report.Clinical case reports · 2026Article
- Review
- Predictors of response and survival in cemiplimab-treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany.Journal of cancer research and clinical oncology · 2026Article
- A Treatment Decision Model for Cutaneous Squamous Cell Carcinoma Based on Bayesian Networks.Cancers · 2026Article
- In Vivo CRISPR Interference Screen Reveals Long Noncoding RNA Portfolio Crucial for Cutaneous Squamous Cell Carcinoma Tumor Growth.The Journal of investigative dermatology · 2026Article
- Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Representing the second most common skin cancer, the incidence and disease burden of cutaneous squamous cell carcinoma (cSCC) continues to increase. Surgical excision of the primary site effectively cures the majority of cSCC cases. However, an aggressive subset of cSCC persists with clinicopathological features that are indicative of higher recurrence, metastasis, and mortality risks. Acceleration of these features is driven by a combination of genetic and environmental factors. The past several years have seen remarkable progress in shaping the treatment landscape for advanced cSCC. Risk stratification and clinical management is a top priority. This review provides an overview of the current perspectives on cSCC with a focus on staging, treatment, and maintenance strategies, along with future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.